Elan Corp, plc (ADR) (NYSE:ELN)
CAPS Rating:
The Company's Biopharmaceuticals unit is engaged in research, development and commercial activities and its EDT unit focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry.
RSS Headlines
Fool UK
Recs
New labeling and new tests for PML from Quest Diagnostics should open up even more markets -- and sales -- to Tysabri.